Eli Lilly (LLY): Препарат Lilly от рака получает статус орфанного препарата FDA

Движение акции сверх рынка по сессиям

В обычных днях (σ): движение LLY сверх её обычной связи с QQQ. Тёмные столбцы — дни с событием сюжета; R — окно отчёта.

Хронология

События сюжета в порядке прихода в нашу ленту, время нью-йоркское. Событие — один факт; показан первый заголовок и до трёх других сообщений о нём.

1. 05.10 14:03

   YFНовый успех Eli Lilly: FDA присвоило статус орфанного препарата лекарству от рака

Оценки по вечерам

Каждый вечер в 22:00 UTC, пока у сюжета были новости за последние три дня. Модель видела только события, пришедшие к этому времени, и дневные движения акции сверх рынка.

Company: LLY (Eli Lilly). Now: 2026-10-07 22:00 UTC (Wednesday).
Storyline: Lilly cancer drug receives FDA orphan drug status
Chronology (UTC):
- 10-05 18:03 Eli Lilly’s Push Beyond Weight Loss Gets Another Boost – FDA Grants Cancer Drug Orphan Drug Status
Stock move beyond the market by session, in typical days (sigma): 09-30 -1.4, 10-01 -0.4, 10-02 -0.4, 10-05 +0.0, 10-06 +0.8, 10-07 +1.6

Company: LLY (Eli Lilly). Now: 2026-10-06 22:00 UTC (Tuesday).
Storyline: Lilly cancer drug receives FDA orphan drug status
Chronology (UTC):
- 10-05 18:03 Eli Lilly’s Push Beyond Weight Loss Gets Another Boost – FDA Grants Cancer Drug Orphan Drug Status
Stock move beyond the market by session, in typical days (sigma): 09-29 -0.0, 09-30 -1.4, 10-01 -0.4, 10-02 -0.4, 10-05 +0.0, 10-06 +0.8

Company: LLY (Eli Lilly). Now: 2026-10-05 22:00 UTC (Monday).
Storyline: Lilly cancer drug receives FDA orphan drug status
Chronology (UTC):
- 10-05 18:03 Eli Lilly’s Push Beyond Weight Loss Gets Another Boost – FDA Grants Cancer Drug Orphan Drug Status
Stock move beyond the market by session, in typical days (sigma): 09-28 +0.1, 09-29 -0.0, 09-30 -1.4, 10-01 -0.4, 10-02 -0.4, 10-05 +0.0

Как модель собирала сюжет

Для каждого события модель видела активные сюжеты компании и выбирала: продолжить один из них, начать новый или считать событие разовым.

1. 05.10 14:03

   Новый сюжет · Новый успех Eli Lilly: FDA присвоило статус орфанного препарата лекарству от рака

   Вопрос и ответ · DeepSeek-V4-Flash, thinking high · s2

   Company: LLY (Eli Lilly)
   New event (10-05 18:03 UTC): Eli Lilly’s Push Beyond Weight Loss Gets Another Boost – FDA Grants Cancer Drug Orphan Drug Status
   
   Storylines:
   1. Lilly-backed TRex Bio files for IPO
      first (10-05 13:14): Eli Lilly-Backed TRex Bio Seeks to Raise $133.3 Million in IPO
   2. Lilly targets amylin pathway for next-gen obesity drug combinations
      first (10-05 13:03): Eli Lilly Targets Amylin Pathway to Unlock Next Generation Obesity Drug Combinations
   3. Gate Bioscience collaboration expansion for difficult-to-drug proteins
      first (10-05 12:04): Gate Bioscience Expands Collaboration and License Agreement with Lilly to Target Difficult-to-Drug Proteins
   4. Foundayo demonstrates cardiovascular safety in large type 2 diabetes trial
      first (09-30 22:02): Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
      latest (10-02 22:46): Eli Lilly’s Foundayo delivers diabetes surprise in late-stage study
   5. Jaypirca FDA approval expansion for CLL/SLL
      first (10-02 19:07): Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
   6. Lilly takes over Milan facility in obesity battle with Novo
      first (10-02 08:20): Lilly Upstages Novo in Fresh Obesity Battle by Taking Over Milan
   7. Lilly dispute with German health policy
      first (10-02 07:01): “My Trust Is Destroyed” Eli Lilly Boss Settles Accounts With German Health Policy - HB
   8. Lilly exits Foghorn collaboration on cancer drug
      first (10-01 12:08): Foghorn plunges as Lilly exits collaboration
      latest (10-01 16:21): Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal
   9. EloraTZP Phase 2 success in obesity and type 2 diabetes
      first (09-30 14:15): Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
      latest (09-30 14:21): Experimental Lilly combination drug tops Zepbound in weight-loss trial
   10. EBGLYSS Phase 3b success in hand and foot atopic dermatitis
      first (09-30 12:05): New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis
   11. Retatrutide phase 3 results show substantial weight loss and A1C reduction
      first (09-29 22:02): Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
      latest (09-30 00:12): ELI LILLY SAYS THE TRIPLE AGONIST ALSO REDUCED A1C IN PEOPLE WITH OBESITY AND TYPE 2 DIABETES, WITH A BIOLOGICS LICENCE APPLICATION PLANNED FOR Q1 2027.
   12. Foundayo shows superiority over oral semaglutide in diabetes analysis
      first (09-29 07:01): Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison
      latest (09-29 16:14): Lilly Stock Drops Lowwer Foundayo Claims an Oral Edge
   
   → {"story": 0, "title": "Lilly cancer drug receives FDA orphan drug status"}